NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris.
"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER ™ Stent System and the EVOLVE study two-year results, which evaluated the SYNERGY ™ Stent System. We believe the results will reinforce our commitment to maintaining a leadership position in the worldwide drug-eluting stent market. We also look forward to sharing results from the REDUCE-HTN study which is evaluating our Vessix ™ Renal Denervation System, a uniquely differentiated technology that offers the precision of bipolar energy delivery. In the structural heart area, we will present data from our REPRISE I and II trials which evaluate the Lotus ™ Aortic Valve System designed to reduce paravalvular leakage. Finally, the set of data presented at EuroPCR includes a series of presentations on our WATCHMAN ™ Left Atrial Appendage Closure device, the most clinically studied technology of its kind."
Schedule of Events All events are Paris time and take place at the Palais des Congres.
Tuesday, May 21 PE PROVE Post-Approval Trial Results Results from the multicenter PROMUS Element™ European Post-Approval Surveillance Trial (PE PROVE) will be presented. The session will showcase one-year outcomes in 1,010 all-comer patients treated with the PROMUS Element Everolimus-Eluting Stent System. The session will be held from 1:36p.m. to 1:43 p.m. in room 243. Speaker: R. Moreno.Wednesday, May 22 NG PROMUS Trial Results The first-in-human results will be presented as a late-breaking clinical trial titled, "Clinical, Angiographic and Intravascular Ultrasound Outcomes of the NG PROMUS Clinical Study Evaluating the Novel Promus PREMIER ™ Everolimus–Eluting Platinum Chromium Stent System." The session will be held from 9:45a.m. to 11:45a.m. in room 243. Speaker: J. Ormiston. EVOLVE Trial Results Two-year clinical outcomes of the EVOLVE study will be presented as a late-breaking clinical trial from 2:10p.m. to 3:10p.m. in room 242AB. Speaker: I. Meredith. Boston Scientific Symposium Featuring The SYNERGY Stent Boston Scientific will host a symposium on its SYNERGY Stent technology featuring a novel bioabsorbable polymer coating. The session, chaired by I. Meredith, is named "Synchronizing polymer absorption and drug elution with the SYNERGY Stent: Implications for healing and dual antiplatelet therapy duration." The session aims to discuss the impact of the polymer on healing, and current evidence when assessing ischemic bleeding and thrombotic risks for specific patient subsets. The symposium will be held from 12:00p.m. to 1:00p.m. in room 251. Speakers: J. Escaned, T. Cuisset and K. Dawkins. REPRISE I and II Trial Results Two presentations will feature data from the clinical program studying the Lotus Valve System:
- REPRISE I
- REPRISE II
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts